Funding Details
- Awarder
- Inbox
- Date Award
- August 02, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Founders
- Emil Kakkis
- Company Description
- Amlogenyx research centers around an enzyme called protective protein/cathepsin A, or PPCA, which can break up a form of amyloid beta, the protein many consider responsible for Alzheimer's debilitating effects.
- Market
- Alzheimer's Disease Treatment
- Location
-
Novato,
California,
USA
- Coinvestors
- GordonMD Global Investments
Links